WO2022026939A3 - Single and dual targeting ligand induced t-cell engager compositions - Google Patents

Single and dual targeting ligand induced t-cell engager compositions Download PDF

Info

Publication number
WO2022026939A3
WO2022026939A3 PCT/US2021/044099 US2021044099W WO2022026939A3 WO 2022026939 A3 WO2022026939 A3 WO 2022026939A3 US 2021044099 W US2021044099 W US 2021044099W WO 2022026939 A3 WO2022026939 A3 WO 2022026939A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
targeting ligand
cell engager
dual targeting
ligand induced
Prior art date
Application number
PCT/US2021/044099
Other languages
French (fr)
Other versions
WO2022026939A2 (en
Inventor
Alexander J. MARTINKO
Erin F. Simonds
Zachary B. Hill
Original Assignee
Soteria Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soteria Biotherapeutics, Inc. filed Critical Soteria Biotherapeutics, Inc.
Priority to TW110128433A priority Critical patent/TW202221015A/en
Publication of WO2022026939A2 publication Critical patent/WO2022026939A2/en
Publication of WO2022026939A3 publication Critical patent/WO2022026939A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention uses a mechanism of "chemically induced dimerization" to enable a precise temporal control of the activity of a T cell engaging complex in a patient. Compositions, methods of making and methods of using such T cell engaging complex are disclosed.
PCT/US2021/044099 2020-07-31 2021-07-31 Single and dual targeting ligand induced t-cell engager compositions WO2022026939A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW110128433A TW202221015A (en) 2020-07-31 2021-08-02 Single and dual targeting ligand induced t-cell engager compositions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063059516P 2020-07-31 2020-07-31
US63/059,516 2020-07-31
US202063083827P 2020-09-25 2020-09-25
US202063083828P 2020-09-25 2020-09-25
US63/083,828 2020-09-25
US63/083,827 2020-09-25

Publications (2)

Publication Number Publication Date
WO2022026939A2 WO2022026939A2 (en) 2022-02-03
WO2022026939A3 true WO2022026939A3 (en) 2022-03-03

Family

ID=80038118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/044099 WO2022026939A2 (en) 2020-07-31 2021-07-31 Single and dual targeting ligand induced t-cell engager compositions

Country Status (2)

Country Link
TW (1) TW202221015A (en)
WO (1) WO2022026939A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022241398A1 (en) * 2021-05-10 2022-11-17 Medimmune, Llc Modified fcrn binding fragments with improved half-life

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170128505A1 (en) * 2015-08-26 2017-05-11 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
WO2018213848A1 (en) * 2017-05-19 2018-11-22 The Regents Of The University Of California Antibody chemically induced dimerizer (abcid) as molecular switches for regulating cellular therapies
WO2021133921A1 (en) * 2019-12-23 2021-07-01 Soteria Biotherapeutics, Inc. Chemically induced association and dissociation of therapeutic fc compositions and chemically induced dimerization of t cell engager with human serum albumin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170128505A1 (en) * 2015-08-26 2017-05-11 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
WO2018213848A1 (en) * 2017-05-19 2018-11-22 The Regents Of The University Of California Antibody chemically induced dimerizer (abcid) as molecular switches for regulating cellular therapies
WO2021133921A1 (en) * 2019-12-23 2021-07-01 Soteria Biotherapeutics, Inc. Chemically induced association and dissociation of therapeutic fc compositions and chemically induced dimerization of t cell engager with human serum albumin

Also Published As

Publication number Publication date
WO2022026939A2 (en) 2022-02-03
TW202221015A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
WO2022026939A3 (en) Single and dual targeting ligand induced t-cell engager compositions
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
EP4006030A3 (en) Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2009126307A3 (en) Factor vii polypeptides that are modified and uses thereof
MX2022001273A (en) Heterotandem bicyclic peptide complex.
AU2016204354A1 (en) Architecture for sharing of current sources in an implantable medical device
EP4279513A3 (en) Cytotoxicity-inducing therapeutic agent
CY1118065T1 (en) INNOVATIVE AMINOGLYCOSIDES AND THEIR USES IN THE TREATMENT OF GENETIC DISORDERS
WO2017100467A3 (en) Compositions and methods for internalizing enzymes
AU2016297195A8 (en) Multi functional toxins
NO20075245L (en) Elimination of heterogeneous or mixed cell population in tumors
WO2007022371A3 (en) Chemokine receptor binding compounds
NZ604056A (en) Novel anti-cmet antibody
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
WO2006091693A3 (en) Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
WO2006135627A3 (en) Inhibitors of akt activity
WO2006138259A3 (en) Chemokine receptor binding compounds
WO2008075370A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
JO2721B1 (en) Artemisinin Derivative Dimers, Their preparation and their therapeutic application
GB0524477D0 (en) Isolated T cell receptors which specifically bind to vygfvracl-hla-24
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
MX2009010988A (en) Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease.
NZ590515A (en) Therapeutic use of specific ligand in msrv associated diseases
PT1848446E (en) Use of iron(iii) complex compounds

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21851534

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 21851534

Country of ref document: EP

Kind code of ref document: A2